冠狀病毒抑制劑|New coronavirus inhibitor
SARS-CoV(SARS冠狀病毒)是引起嚴(yán)重急性呼吸道綜合癥(SARS)的病毒。 冠狀病毒編碼的木瓜蛋白酶樣蛋白酶(PLpro)通常是具有蛋白酶活性的多功能酶,具有加工病毒復(fù)制酶多蛋白和去泛素化(DUB)/ deISGylating活性的作用,假定該酶可以修飾對(duì)感染的先天免疫應(yīng)答。冠狀病毒抑制劑主要用于新型新型冠狀病毒的先導(dǎo)化合物,進(jìn)行抗新型冠狀病毒(2019-nCoV)潛在藥物的篩選研究和新藥研發(fā)使用,不可直接應(yīng)用于人體使用。The study of the structure of virus is an important implication for the exploring and development of effective antivirals. At present, S protein, TMPRSS2, ACE2, RdRp, and Mpro are primary targets. For example, Lopinavir as a protease inhibitor combined with Ritonavir performs against antiretroviral activity. Remdesivir, as a nucleotide analogue, shows an effective activity against SARS-CoV-2 through inhibiting RdRp.



購物車 


